The role of fibroblast growth factors and their receptors in prostate cancer.

Prostate cancer is the most common malignancy in men in the USA and the second leading cause of cancer deaths. Fibroblast growth factors (FGFs), including FGF1 (acidic FGF), FGF2 (basic FGF), FGF6 and FGF8 are all expressed at increased levels in prostate cancer as paracrine and/or autocrine growth factors for the prostate cancer cells. In addition, increased mobilization of FGFs from the extracellular matrix in cancer tissues can increase the availability of FGFs to cancer cells. Prostate cancer epithelial cells express all four types of FGF receptors (FGFR-1 to -4) at variable frequencies. Expression of FGFR-1 and FGFR-4 is most closely linked to prostate cancer progression, while the role of FGFR-2 remains controversial. Activation of FGF receptors can activate multiple signal transduction pathways including the phospholipase Cgamma, phosphatidyl inositol 3-kinase, mitogen-activated protein kinase and signal transducers and activators of transcription (STAT) pathways, all of which play a role in prostate cancer progression. Sprouty proteins can negatively regulate FGF signal transduction, potentially limiting the impact of FGF signaling in prostate cancer, but in a significant fraction of prostate cancers there is decreased expression of Sprouty1 mRNA and protein. The effects of increased FGF receptor signaling are wide ranging and involve both the cancer cells and surrounding stroma, including the vasculature. The net result of increased FGF signaling includes enhanced proliferation, resistance to cell death, increased motility and invasiveness, increased angiogenesis, enhanced metastasis, resistance to chemotherapy and radiation and androgen independence, all of which can enhance tumor progression and clinical aggressiveness. For this reason, the FGF signaling system it is an attractive therapeutic target, particularly since therapies targeting FGF receptors and/or FGF signaling can affect both the tumor cells directly and tumor angiogenesis. A number of approaches that could target FGF receptors and/or FGF receptor signaling in prostate cancer are currently being developed.

[1]  M. Brawer,et al.  Expression of metalloproteinase genes in human prostate cancer , 2005, Journal of Cancer Research and Clinical Oncology.

[2]  C. Coopersmith,et al.  Epithelial cells , 1991 .

[3]  M. Ittmann,et al.  The Fibroblast Growth Factor Receptor-4 Arg388 Allele Is Associated with Prostate Cancer Initiation and Progression , 2004, Clinical Cancer Research.

[4]  Patricia D. Castro,et al.  The Expression of Sprouty1, an Inhibitor of Fibroblast Growth Factor Signal Transduction, Is Decreased in Human Prostate Cancer , 2004, Cancer Research.

[5]  M. Ittmann,et al.  FGF17 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasia , 2004, The Prostate.

[6]  Dingcai Cao,et al.  A Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in Hormone-Refractory Prostate Cancer , 2004, Clinical Cancer Research.

[7]  A. Chase,et al.  Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074 , 2004, Leukemia.

[8]  N. Hynes,et al.  Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins , 2004, Oncogene.

[9]  O. Blaschuk,et al.  Induction of apoptosis in cultured endothelial cells by a cadherin antagonist peptide: involvement of fibroblast growth factor receptor-mediated signalling. , 2004, Experimental cell research.

[10]  R. V. van Etten,et al.  Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. , 2004, Cancer cell.

[11]  J. Bernhagen,et al.  Unconventional Secretion of Fibroblast Growth Factor 2 Is Mediated by Direct Translocation across the Plasma Membrane of Mammalian Cells , 2004, Journal of Biological Chemistry.

[12]  M. Ittmann,et al.  Inhibition of proliferation and survival of melanoma cells by adenoviral-mediated expression of dominant negative fibroblast growth factor receptor , 2004, Melanoma research.

[13]  F. Blasi,et al.  The urokinase plasminogen activator system in cancer: Recent advances and implication for prognosis and therapy , 2003, Cancer and Metastasis Reviews.

[14]  Shereen El-Shorbagy.  EVALUATION OF THE RESPONSE TO LEUPROLIDE ACETATE (LUPRON DEPOT - 3 MONTH 11.25mg) (GNRH AGONIST) IN PRIMARY HEPATOCELLULAR CARCINOMA AND ITS RELATION TO ANDROGEN RECEPTOR , 2004 .

[15]  M. Ittmann,et al.  Chronic activity of ectopic type 1 fibroblast growth factor receptor tyrosine kinase in prostate epithelium results in hyperplasia accompanied by intraepithelial neoplasia , 2004, The Prostate.

[16]  T. Dougherty,et al.  Anti-Angiogenic Activity of Selected Receptor Tyrosine Kinase Inhibitors, PD166285 and PD173074: Implications for Combination Treatment with Photodynamic Therapy , 2004, Investigational New Drugs.

[17]  P. Dell’Era,et al.  Shedding of Membrane Vesicles Mediates Fibroblast Growth Factor-2 Release from Cells* , 2003, Journal of Biological Chemistry.

[18]  M. Ittmann,et al.  Cooperation between ectopic FGFR1 and depression of FGFR2 in induction of prostatic intraepithelial neoplasia in the mouse prostate. , 2003, Cancer research.

[19]  M. Ittmann,et al.  Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. , 2003, Cancer research.

[20]  T. Tamiya,et al.  Reduction of infarct volume and apoptosis by grafting of encapsulated basic fibroblast growth factor-secreting cells in a model of middle cerebral artery occlusion in rats. , 2003, Journal of neurosurgery.

[21]  D. Tindall,et al.  p300 in prostate cancer proliferation and progression. , 2003, Cancer research.

[22]  J. Bartlett,et al.  Gene amplifications associated with the development of hormone-resistant prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  Mustafa Ozen,et al.  Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. , 2003, Cancer research.

[24]  R. Nagle,et al.  Pharmacological inhibition of FGF receptor signaling inhibits LNCaP prostate tumor growth, promatrilysin, and PSA expression , 2003, Molecular carcinogenesis.

[25]  Leif E. Peterson,et al.  Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. , 2003, Cancer research.

[26]  H. Klocker,et al.  Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia , 2003, The Prostate.

[27]  S. Wadsworth,et al.  Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  J. Debus,et al.  SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. , 2003, Cancer research.

[29]  Xia Zhao,et al.  Inhibition of Tumor Growth with a Vaccine Based on Xenogeneic Homologous Fibroblast Growth Factor Receptor-1 in Mice* , 2003, Journal of Biological Chemistry.

[30]  C. Robson,et al.  FGF8 isoform b expression in human prostate cancer , 2003, British Journal of Cancer.

[31]  Ivan Dikic,et al.  Negative receptor signalling. , 2003, Current opinion in cell biology.

[32]  L. Bubendorf,et al.  Tissue microarray analysis reveals prognostic significance of syndecan‐1 expression in prostate cancer , 2003, The Prostate.

[33]  W. Schulz,et al.  Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications. , 2003, European urology.

[34]  M. Knowles,et al.  Fibroblast growth factors and their receptors in transitional cell carcinoma. , 2003, The Journal of urology.

[35]  Y. Doki,et al.  Overexpression of cyclin D1 contributes to malignancy by up-regulation of fibroblast growth factor receptor 1 via the pRB/E2F pathway. , 2003, Cancer research.

[36]  B. Foster,et al.  Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression , 2003, The Prostate.

[37]  B. Foster,et al.  Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. , 2002, Differentiation; research in biological diversity.

[38]  C. Bucana,et al.  Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel. , 2002, Cancer research.

[39]  R. Cardiff,et al.  Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia. , 2002, Cancer research.

[40]  A. Aigner,et al.  Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo , 2002, Oncogene.

[41]  O. Cussenot,et al.  Down‐regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate , 2002, The Prostate.

[42]  F. Zunino,et al.  Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  N. Bazan,et al.  Phosphorylation of STAT-3 in Response to Basic Fibroblast Growth Factor Occurs through a Mechanism Involving Platelet-activating Factor, JAK-2, and Src in Human Umbilical Vein Endothelial Cells , 2002, The Journal of Biological Chemistry.

[44]  I. Lax,et al.  FRS2α attenuates FGF receptor signaling by Grb2- mediated recruitment of the ubiquitin ligase Cbl , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[45]  W. Mckeehan,et al.  Fibroblast growth factor receptor 1 phosphotyrosine 766: molecular target for prevention of progression of prostate tumors to malignancy. , 2002, Cancer research.

[46]  J. Cherrington,et al.  Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. , 2002, Cancer research.

[47]  H. Höfler,et al.  Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. , 2002, Cancer research.

[48]  R. Nagle,et al.  Fibroblast growth factor-1 induced promatrilysin expression through the activation of extracellular-regulated kinases and STAT3. , 2002, Neoplasia.

[49]  C. Bucana,et al.  Inhibition of Growth and Metastasis of Orthotopic Human Prostate Cancer in Athymic Mice by Combination Therapy with Pegylated Interferon-- 2 b and Docetaxel , 2002 .

[50]  J. Melo,et al.  The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. , 2001, Blood.

[51]  M. Ittmann,et al.  Role of fibroblast growth factor receptor signaling in prostate cancer cell survival. , 2001, Journal of the National Cancer Institute.

[52]  N. Bouck,et al.  Thrombospondin‐1, vascular endothelial growth factor and fibroblast growth factor‐2 are key functional regulators of angiogenesis in the prostate , 2001, The Prostate.

[53]  M. Wientjes,et al.  Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. , 2001, The Journal of pharmacology and experimental therapeutics.

[54]  D. Neal,et al.  Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer , 2001, British Journal of Cancer.

[55]  P. Stern,et al.  Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours , 2001, Oncogene.

[56]  I. Lax,et al.  Critical role for the docking-protein FRS2α in FGF receptor-mediated signal transduction pathways , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[57]  M. Ittmann,et al.  Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. , 2001, The American journal of pathology.

[58]  M. Nevalainen,et al.  Increased Expression of FGF-8 Isoforms and FGF Receptors in Human Premalignant Prostatic Intraepithelial Neoplasia Lesions and Prostate Cancer , 2001, Laboratory Investigation.

[59]  A. Wellstein,et al.  An FGF‐binding protein (FGF‐BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF‐2 release , 2001, International journal of cancer.

[60]  M. Goldfarb,et al.  Fibroblast growth factor homologous factors are intracellular signaling proteins , 2001, Current Biology.

[61]  P. L. Bergsagel,et al.  The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. , 2001, Blood.

[62]  S C Robertson,et al.  Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation. , 2001, Molecular biology of the cell.

[63]  Nobuyuki Itoh,et al.  Fibroblast growth factors , 2001, Genome Biology.

[64]  M. Ittmann,et al.  Alternative splicing of fibroblast growth factor receptors in human prostate cancer , 2001, The Prostate.

[65]  M. Sakanaka,et al.  The expression of basic fibroblast growth factor and vascular endothelial growth factor in prostatic adenocarcinoma: correlation with neovascularization. , 2001, Anticancer research.

[66]  G. Miller,et al.  The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells. , 2000, Cancer research.

[67]  D. Neal,et al.  Serum keratinocyte growth factor measurement in patients with prostate cancer. , 2000, The Journal of urology.

[68]  D. Neal,et al.  Fibroblast growth factor receptor‐2 mutation analysis in human prostate cancer , 2000, BJU international.

[69]  M. Ittmann,et al.  FGF‐10 Is expressed at low levels in the human prostate , 2000, The Prostate.

[70]  C. Powers,et al.  Fibroblast growth factors, their receptors and signaling. , 2000, Endocrine-related cancer.

[71]  M. Ittmann,et al.  Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer. , 2000, Cancer research.

[72]  O. Cussenot,et al.  No evidence for fibroblast growth factor receptor 3 (FGFR‐3) R248C/S249C mutations in human prostate cancer , 2000, International journal of cancer.

[73]  J. Au,et al.  Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[74]  A. N. Meyer,et al.  Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4 , 2000, Oncogene.

[75]  M. Ittmann,et al.  Interleukin-1α Is a Paracrine Inducer of FGF7, a Key Epithelial Growth Factor in Benign Prostatic Hyperplasia , 2000 .

[76]  R. deVere White,et al.  Fibroblast growth factor 2: its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions. , 2000, Urology.

[77]  L. Citores,et al.  Requirement of Phosphatidylinositol 3-Kinase Activity for Translocation of Exogenous aFGF to the Cytosol and Nucleus* , 2000, The Journal of Biological Chemistry.

[78]  B. O’Malley,et al.  Phosphorylation of Steroid Receptor Coactivator-1 , 2000, The Journal of Biological Chemistry.

[79]  E. Fearon,et al.  Cancer progression , 1999, Current Biology.

[80]  W. Mcdougal,et al.  Immunolocalization of the keratinocyte growth factor in benign and neoplastic human prostate and its relation to androgen receptor , 1999, The Prostate.

[81]  G. T. Bowden,et al.  Promatrilysin expression is induced by fibroblast growth factors in the prostatic carcinoma cell line LNCaP but not in normal primary prostate epithelial cells , 1999, The Prostate.

[82]  D. Neal,et al.  aFGF immunoreactivity in prostate cancer and its co‐localization with bFGF and FGF8 , 1999, The Journal of pathology.

[83]  B. Shilo,et al.  Sprouty is a general inhibitor of receptor tyrosine kinase signaling. , 1999, Development.

[84]  D. Chopin,et al.  Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.

[85]  P. Davol,et al.  Targeting human prostatic carcinoma through basic fibroblast growth factor receptors in an animal model: Characterizing and circumventing mechanisms of tumor resistance , 1999, The Prostate.

[86]  M. Ittmann,et al.  FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation. , 1999, The Journal of urology.

[87]  O. Cussenot,et al.  FGF7/KGF triggers cell transformation and invasion on immortalised human prostatic epithelial PNT1A cells , 1999, International journal of cancer.

[88]  M. Ittmann,et al.  FGF9 is an autocrine and paracrine prostatic growth factor expressed by prostatic stromal cells , 1999, Journal of cellular physiology.

[89]  L. Thompson,et al.  Comparison of the intracellular signaling responses by three chimeric fibroblast growth factor receptors in PC12 cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[90]  N. Hacohen,et al.  Sprouty: a common antagonist of FGF and EGF signaling pathways in Drosophila. , 1999, Development.

[91]  M. Ittmann,et al.  Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[92]  D. Rifkin,et al.  Nuclear activities of basic fibroblast growth factor: potentiation of low-serum growth mediated by natural or chimeric nuclear localization signals. , 1999, Molecular biology of the cell.

[93]  D. Neal,et al.  FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease , 1999, Oncogene.

[94]  Matthew Freeman,et al.  Sprouty, an Intracellular Inhibitor of Ras Signaling , 1999, Cell.

[95]  B. Foster,et al.  Characterization of the FGF axis and identification of a novel FGFR1iiic isoform during prostate cancer progression in the TRAMP model , 1999, Prostate Cancer and Prostatic Diseases.

[96]  D. Warburton,et al.  Conserved function of mSpry-2, a murine homolog of Drosophila sprouty, which negatively modulates respiratory organogenesis , 1999, Current Biology.

[97]  A. De Benedetti,et al.  eIF4E expression in tumors: its possible role in progression of malignancies. , 1999, The international journal of biochemistry & cell biology.

[98]  W. Mcdougal,et al.  Androgen responsiveness of stromal cells of the human prostate: regulation of cell proliferation and keratinocyte growth factor by androgen. , 1998, The Journal of urology.

[99]  Hiroaki Takahashi.  STUDIES ON THE EXPERSSION OF FIBROBLAST GROWTH FACTORS AND FIBROBLAST GROWTH FACTOR RECEPTORS IN HUMAN PROSTATE CANCER , 1998 .

[100]  D. Rose,et al.  Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice. , 1998, The Journal of urology.

[101]  I. Chiu,et al.  Regulation of a promoter of the fibroblast growth factor 1 gene in prostate and breast cancer cells , 1998, The Journal of Steroid Biochemistry and Molecular Biology.

[102]  D. Ornitz,et al.  FGF signaling in skeletal development. , 1998, Frontiers in bioscience : a journal and virtual library.

[103]  I. Lax,et al.  Binding of Shp2 Tyrosine Phosphatase to FRS2 Is Essential for Fibroblast Growth Factor-Induced PC12 Cell Differentiation , 1998, Molecular and Cellular Biology.

[104]  M. Fukayama,et al.  High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8. , 1998, Cancer research.

[105]  S. Tsang,et al.  Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[106]  A. Matsubara,et al.  Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2. , 1998, Cancer research.

[107]  R. Klemke,et al.  Integrin αvβ3 Requirement for Sustained Mitogen-activated Protein Kinase Activity during Angiogenesis , 1998, The Journal of cell biology.

[108]  N. Rudra-Ganguly,et al.  Downregulation of human FGF8 activity by antisense constructs in murine fibroblastic and human prostatic carcinoma cell systems , 1998, Oncogene.

[109]  H. Takahashi.  [Studies on the expression of fibroblast growth factors and fibroblast growth factor receptors in human prostate cancer]. , 1998, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

[110]  J. Nemeth,et al.  Keratinocyte growth factor in the rat ventral prostate: androgen-independent expression. , 1998, The Journal of endocrinology.

[111]  T. Hudson,et al.  FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome , 1998, Nature Genetics.

[112]  Russ P Carstens,et al.  Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer , 1997, Oncogene.

[113]  A. Matsubara,et al.  Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. , 1997, Cancer research.

[114]  H. Klocker,et al.  Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate , 1997, The Prostate.

[115]  D. Bar-Sagi,et al.  A Lipid-Anchored Grb2-Binding Protein That Links FGF-Receptor Activation to the Ras/MAPK Signaling Pathway , 1997, Cell.

[116]  S. Hubbard,et al.  Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. , 1997, Science.

[117]  C. Bucana,et al.  Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. , 1997, The American journal of pathology.

[118]  S. Hayward,et al.  Stromal-epithelial interactions in the normal and neoplastic prostate. , 1997, British journal of urology.

[119]  M. Ittman,et al.  Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate. , 1997, The Journal of urology.

[120]  G. Miller,et al.  Molecular cloning and characterization of human FGF8 alternative messenger RNA forms. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[121]  C. MacArthur,et al.  Receptor Specificity of the Fibroblast Growth Factor Family* , 1996, The Journal of Biological Chemistry.

[122]  J. C. Fox,et al.  Antisense Inhibition of Basic Fibroblast Growth Factor Induces Apoptosis in Vascular Smooth Muscle Cells (*) , 1996, The Journal of Biological Chemistry.

[123]  L. Matrisian,et al.  Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. , 1996, The international journal of biochemistry & cell biology.

[124]  R. Nagle,et al.  Matrilysin expression in human prostate carcinoma , 1996, Molecular carcinogenesis.

[125]  D. Ron,et al.  Fibroblast growth factor receptors display both common and distinct signaling pathways. , 1995, Oncogene.

[126]  R. Coombes,et al.  bFGF and aFGF induce membrane ruffling in breast cancer cells but not in normal breast epithelial cells: FGFR-4 involvement. , 1995, The Biochemical journal.

[127]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[128]  Jack P. Witty,et al.  Expression and localization of matrix‐degrading metalloproteinases during colorectal tumorigenesis , 1994, Molecular carcinogenesis.

[129]  W. Mckeehan,et al.  Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy , 1993, Molecular and cellular biology.

[130]  A. Logan,et al.  Angiogenesis , 1993, The Lancet.

[131]  T M Grogan,et al.  Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. , 1993, Cancer research.

[132]  R. Nagle,et al.  Functional role of the metalloproteinase matrilysin in human prostate cancer (ASTRO research fellowship) , 1993 .

[133]  D. Johnson,et al.  Structural and functional diversity in the FGF receptor multigene family. , 1993, Advances in cancer research.

[134]  W. Mckeehan,et al.  Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin. , 1992, Molecular endocrinology.

[135]  D. Moscatelli,et al.  The FGF family of growth factors and oncogenes. , 1992, Advances in cancer research.

[136]  M. Jaye,et al.  A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1 , 1991, Molecular and cellular biology.

[137]  M. Hendrix,et al.  The role of the matrix metalloproteinase stromelysin in the progression of squamous cell carcinomas. , 1991, The American journal of the medical sciences.

[138]  M. Gleave,et al.  Reciprocal mesenchymal-epithelial interaction affecting prostate tumour growth and hormonal responsiveness. , 1991, Cancer surveys.

[139]  P. Chambon,et al.  A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas , 1990, Nature.

[140]  A. Zilberstein,et al.  Characterization and cDNA cloning of phospholipase C-gamma, a major substrate for heparin-binding growth factor 1 (acidic fibroblast growth factor)-activated tyrosine kinase , 1990, Molecular and cellular biology.

[141]  T. Stamey,et al.  Clonal growth of human prostatic epithelial cells is stimulated by fibroblasts , 1989, The Prostate.